ArticleBritish journal of cancer2012

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.

C Nabhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.